P2Y12 Inhibitor Monotherapy Combined With Colchicine Following PCI in ACS Patients: The MACT Pilot Study

Seung-Yul Lee, Young-Hoon Jeong, Kyeong Ho Yun, Jae Young Cho, Diana Gorog, Dominick J. Angiolillo, Kim Jin Won, Yangsoo Jang

Research output: Contribution to journalArticlepeer-review

Abstract

This proof-of-concept pilot trial investigated the feasibility of ticagrelor or prasugrel P2Y12 inhibitor monotherapy combined with colchicine immediately after PCI in ACS patients. The day after PCI, aspirin was replaced with low-dose colchicine (0.6 mg daily) on ticagrelor or prasugrel maintenance. Among 200 ACS patients enrolled, stent thrombosis occurred in two patients for 3 months. High platelet reactivity assessed by VerifyNow assay was low at discharge and hs-CRP levels decreased significantly within 1 month after PCI. Accordingly, P2Y12 inhibitor mono antiplatelet and colchicine therapy is feasible in ACS patients undergoing PCI and associated with favorable platelet function and inflammatory profiles.
Original languageEnglish
Pages (from-to)1845-1855
Number of pages11
JournalJACC: Cardiovascular Interventions
Volume16
Issue number15
Early online date14 Aug 2023
DOIs
Publication statusPublished - 14 Aug 2023

Fingerprint

Dive into the research topics of 'P2Y12 Inhibitor Monotherapy Combined With Colchicine Following PCI in ACS Patients: The MACT Pilot Study'. Together they form a unique fingerprint.

Cite this